Clinically superior scalp cooling
Hair loss is no longer inevitable
FDA cleared for men and women with solid tumor cancers
Clinically superior scalp cooling
Hair loss is no longer inevitable
FDA cleared for men and women with solid tumor cancers

Dignitana AB produces
The DigniCap Scalp Cooling System to minimize hair loss from chemotherapy.

Click HERE to learn more about DigniCap Delta.

DigniCap is designed to safely provide uniform scalp cooling with high efficiency and acceptable comfort. The system consists of a tightly fitting silicone cap that is connected to a cooling and control unit, as well as an insulating neoprene outer cap to maintain fit and the treatment temperature.

The patented DigniCap system has shown excellent scientific results in clinical studies– 67% of patients had a successful outcome and retained their hair in the pivotal trial which led to FDA clearance in 2015.

For product information, visit


Company Profile

Dignitana is a Swedish medical technology company publicly traded on Nasdaq First North Growth Market. Company headquarters are in Lund, Sweden and operations are based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy.

The company develops, produces and markets The DigniCap® Scalp Cooling System. It is a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy to improve well-being and quality of life. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and acceptable patient comfort. In 2017, Dignitana received an expanded clearance from the FDA, allowing DigniCap to be used by patients receiving chemotherapy to treat solid tumors from breast cancer as well as those from prostate, ovarian, uterine, lungs and other tissues.


Annual General Meeting
25 May 2023
Click here to read more

Q4 Report  
16 February 2023
Click here for Financial Reports


Dignitana: Intervju med vd Catarina Löwenadler (video)

20 February 2023

Redeye har intervjuat Catarina Löwenadler Vd på Dignitana i samband med Q4 rapporten. Vi diskuterade den positiva utvecklingen samt utmaningar inför 2023.


18 October 2022
Presentation by Catarina Mård Löwenadler, CEO
18 October 2022
Intervju med Cataringa Mård Löwenadler, vd för Dignitana
9 June 2022
Interview with CEO Catarina Mård Löwenadler
Saving Identity
1 September 2019
In the film “Saving Identity” Dr. Hope Rugo of UCSF explains how scalp cooling reduces hair loss from chemo and the process from gaining approval for the first FDA cleared scalp cooling system in the US in 2015 to the launch of the new DigniCap Delta device in 2019.


Redeye Research Note
18 November 2022
Redeye Research Note
17 November 2023

Please note that the content of this website is not intended as professional medical or healthcare advice and should not be construed as a substitute for professional healthcare advice, or services from a qualified professional healthcare provider familiar with your unique situation. This content is intended solely as a general product and corporate information.

10925 Estate Lane, Suite 185
Dallas, TX 75238
+1 469-917-5555

Dignitana AB
Traktorgränden 3
226 60 Lund, Sweden
+46 46 16 30 90

Dignitana S.r.l.
Corso di Porta Nuova, 46
20121 Milan, Italy